Pharvaris NV
PHVSHealthcare|Biotechnology|Netherlands
$35.02
-0.86 (-2.39%)
Tangible Book
$4.18
Earnings Power
$4.31
Clinical Trials (8)
| Trial | Conditions | Phase | Status | Enrollment | Design | Drug |
|---|---|---|---|---|---|---|
| NCT05834777 Prevention of Intradialytic Hypotension by Inhibiting Bradykinin B2 Receptor | Intradialytic Hypotension | P3 | Recruiting | 26 | RCT, Double-blind | Icatibant, Placebo |
| NCT06669754 Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | Hereditary Angioedema (HAE) | P3 | Active | 81 | RCT, Double-blind | Deucrictibant, Placebo |
| NCT07266805 Study of Oral Deucrictibant XR Tablet for Prophylaxis and Deucrictibant IR Capsule for On-Demand Treatment of Angioedema Attacks in Adults With Acquired Angioedema Due to C1 Inhibitor Deficiency | Acquired Angioedema Due to C1-Inhibitor Deficiency (AAE-C1-INH) | P3 | Recruiting | 32 | RCT, Double-blind | Deucrictibant, Placebo, Deucrictibant, Placebo, Deucrictibant |
| NCT06679881 Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE | Hereditary Angioedema (HAE) | P3 | Recruiting | 170 | Open-label | Deucrictibant |
| NCT05396105 Extension Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | Hereditary Angioedema, Hereditary Angioedema Type I | P2P3 | By Invite | 150 | Open-label | deucrictibant, deucrictibant |
| NCT06343779 Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema | Hereditary Angioedema, Hereditary Angioedema Type I | P3 | Completed | 134 | RCT, Double-blind | Deucrictibant, Placebo |
| NCT05047185 Dose-ranging Study of Oral PHA-022121 for Prophylaxis Against Angioedema Attacks in Patients With Hereditary Angioedema Type I or Type II | Hereditary Angioedema, Hereditary Angioedema Type I | P2 | Completed | 34 | RCT, Double-blind | Deucrictibant low dose, Deucrictibant high dose, Placebo |
| NCT04618211 Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema | Hereditary Angioedema, Hereditary Angioedema Type I | P2 | Completed | 74 | RCT, Double-blind | Deucrictibant, Placebo |